VK2809: Patent expiry in US, Australia, Canada and PCT between 2025 to 2038 (Viking Therapeutics) - Mar 22, 2018 - Annual Report 2017
Patent • Fibrosis • Immunology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
|